Has Ellen Lathi received payments from drug or device companies?

Yes. Drug and device makers reported $90,356 in general payments to Ellen Lathi across 154 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ellen Lathi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ellen Lathi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ellen Lathi

Neurology · Wellesley, MANPI 1740276674

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Biogen at 43.0% of the total. Reporting peaked in 2019 at $71,301 and has fallen 99.9% since, to $50 in 2024. Among neurology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$90,356in general payments, 2019–2025

Across 154 payments — averaging $586.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Biogen$39K
Genentech USA, Inc.$34K
EMD Serono, Inc.$9K
Genentech, Inc.$6K
Sanofi$2K
Novartis$416
plus $159 from 3 others

$1,146,397in research payments, 2019–2025

Across 114 payments — averaging $10,056 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Biogen$720K
Genentech, Inc.$297K
Sanofi$63K
F. Hoffmann-la Roche AG$44K
Novartis$23K

What the payments were for

Consulting fees$49,91955%
Speaking & faculty fees$28,91032%
Travel & lodging$6,4307%
Food & beverage$5,0276%
Education$710%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Biogen	75	$38,894
Genentech USA, Inc.	33	$34,040
EMD Serono, Inc.	16	$8,812
Genentech, Inc.	6	$5,956
Sanofi	11	$2,079
Novartis	9	$416
Sanofi-aventis U.S. LLC	1	$93
Amgen	2	$50
AstraZeneca	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OCREVUS$39,559
TYSABRI$20,471
Mavenclad$7,874
Non-Covered Product$6,080
AUBAGIO$1,828
AVONEX$113

How this compares

$90,356 in reported general payments places this provider in the 90th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Other neurology in Wellesley

Joshua KatzWellesley$462K
Kenneth GorsonWellesley$414K
Andrew BouleyWellesley$308K
Christopher WrightBoston$2.5M
Shivang JoshiWestborough$1.2M
Egilius SpieringsWellesley Hills$680K
Thomas ScammellBoston$617K
Salvatore NapoliFoxboro$613K
Alfred SandrockBoston$490K
Guy BuckleBrookline$450K

See the full list for Massachusetts →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →